Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

User Fee Bill Or Drug Pricing Bill? House Members Makes Both Cases

Jul 13 2017

• By Derrick Gingery and Michael Cipriano

Related Content

FDA/Generic Communications Plan Restoring Best Of Past Practices

Dec 18 2014

Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul

Sep 17 2016

US FDA Promises Shorter, Quicker Drug GMP Warning Letters

Jul 01 2016

FDA’s Drug Shortage Anniversary A Happy Occasion For The Agency

May 03 2012

FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds

Jul 21 2016

FDA Aligns New Pharmaceutical Inspectorate Into Six Divisions

May 17 2017

Generic Drug Sponsors Seek Advance Notice Of Approvals From US FDA

May 17 2017

Pediatric Cancer Study Requirements Added To FDA User Fee Bill

Jul 12 2017

Generic Drugs: First-Cycle Review Times Improve, But Hundreds Of ANDAs Still Pending

Jul 04 2017

US FDA Might Face Funding Penalty For Missing User Fee Goals

Apr 04 2017

Breakthrough-Style Program For ANDAs Added To House User Fee Bill

May 19 2017

Generic Priority Review Expanded In Senate User Fee Bill

May 12 2017

Expanded Access Amendment Could Blunt 'Right To Try' Legislation In US

May 12 2017

FDA's White Oak Staff May Move Off-Site To Ease Space Crunch

May 31 2017

User Fee Add-Ons: Senate Bill Tweaks Orphans, Opioids, Patient Data

May 09 2017

FDA Faces Budget Crunch In 2023 Under User Fee Legislation

Jul 13 2017

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

Sep 24 2016

Generic User Fees: FDA Goes On Backlog Offensive

Oct 16 2015

FDA User Fee Bill: House Cmte. Makes Technical Changes, Adds Pricing Resolution

Jun 08 2017

Generic Industry Gets 267 Reasons From FDA To Pursue ANDA Development

Jun 28 2017

FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit

Jun 28 2017

Drug Pricing Hearing In Senate Postponed, Handing Innovators Another Victory

Jun 29 2017

Additional Topics

United States FDA Drug Review Legislation Policy BioPharmaceutical

More from US FDA

More from Agency Leadership

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window